CINC280A2201

Status: Active Trial | Marker: MET Title A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) Study Number NCT02414139 Indication NSCLC harbouring MET mutation in second...